Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.
EP. 6: Updates from IMbrave150, LEAP-002, and HIMALAYA Trials
April 30th 2024Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma.
EP. 8: The Evolving Landscape of Second-Line Therapies in HCC Management
May 7th 2024Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.